Kaerus Bioscience

Approval stamp
#Drug approvals #Fragile X Syndrome #Kaerus Bioscience #Regulatory

Approvals granted for the treatment of Fragile X Syndrome 

Kaerus Bioscience’s lead candidate KER-0193 has been granted both Orphan Drug Designation and Rare Pediatric Drug Designations for the treatment of Fragile X syndrome (FXS) by the US Food and Drugs Administration (FDA). This follows the recent successful completion of a Phase I trial of KER-0193 in healthy volunteers, which… Read More

#News #Regulatory